Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1996-03-20
1999-03-02
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
600 1, A61K 3119, A61K 31557, A61N 500
Patent
active
058772154
ABSTRACT:
The invention is directed to a method of increasing ionizing radiation's cytotoxic effects on a neoplasm in a subject by increasing the neoplasm's sensitivity to ionizing radiation, comprising administering a therapeutically effective amount of prostaglandin to the subject, and subjecting the neoplasm to a therapeutically effective amount of ionizing radiation, thereby increasing the cytotoxic effects of the ionizing radiation on the neoplasm. The invention is further directed to a method of reducing the therapeutically effective amount of ionizing radiation required to treat a neoplasm in a subject, compared to treating with ionizing radiation alone, comprising administering a therapeutically effective amount of prostaglandin to the subject, thereby reducing the therapeutically effective amount of ionizing radiation required to treat the neoplasm in the subject, compared to treating with ionizing radiation alone, and subjecting the neoplasm in the subject to the reduced therapeutically effective amount of ionizing radiation. The invention is also directed to a method of treating a neoplasm in a subject, comprising administering a therapeutically effective amount of prostaglandin and administering a therapeutically effective amount of cisplatin to the subject, wherein the therapeutically effective amount of the platinum-based anti-tumor agent is less than 60 mg/meter.sup.2.
REFERENCES:
McClay, E.F., Winski, P.J., Jones, J.A., Jenrette, III, J.M., Gattoni-Celli, S. ".DELTA..sup.12 -Prostaglandin J.sub.2 is cytotoxic alone and synergizes in combination with both cisplatin and radiation in human malignancies" Abstract #2696, Proceedings of the Am. Assoc. for Cancer Research vol. 37, p. 395, Mar. 1996.
Lee, Jeong-Hwa, Kim, Ho-Shik, Jeong Seong-Yun, Kim, In-Kyung "Induction of p53 and apoptosis by .DELTA..sup.12 -PGJ.sub.2 in human hepatocarcinoma SK-HEP-1 cells" FEBS Letters 368:348-352, Feb. 1995.
McClay, E.F., Albright, K.A., Jones, J.A., Christen, R., and Howell, S.B. "Tamoxifen delays the development of resistance to cisplatin in human malanoma and ovarian cancer cell lines", Br. J. Cancer, 70: 449-452, 1994.
McClay, E.F., Albright, K.A., Jones, J.A., Christen, R., and Howell, S.B. "Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells", Cancer Res., 53: 1571-1576, Apr. 1, 1993.
Kim, I.K., Lee, J.H., Sohn, H.W., Kim, H.S., and Kim, S.H. "Prostaglandin A.sub.2 and .DELTA..sup.12 -prostaglandin J.sub.2 induce apoptosis in L1210 cells", Fed Europ Biochem Soc, 321: 209-214, Apr. 1993.
Sasaguri, T., Masuda, J., Shimokada, K., Yokoto, T., Kosaka, C., Fujishima, M., and Ogata, J. "Prostaglandins A and J arrest the cell cycle of cultured vascular smooth muscle cells without suppression of c-myc expression", Exp. Cell Res., 200: 351-357, 1992.
Fukushima, M. "Biological activities and mechanisms of action of PG J.sub.2 and related compounds: an update", Prostagl, Leukotri. Essen. Fatty Acids, 47: 1-12, 1992.
Choi, A.M.K., Fargnoli, J., Carlson, S.G., and Holbrook, N.J. "Cell growth inhibition by prostaglandin A.sub.2 results in elevated expression of gadd153 mRNA", Exp. Cell Res., 199: 85-89, 1992.
Santoro, M.G., Garaci, E., and Amici, C. "Induction of heat shock protein synthesis by prostaglandis with antineoplastic and antiviral activity", Adv. prostaglandin, Thromboxane, and Leukotriene Res. 21:867-874, 1990.
Fornace, A.J., Nebert, D.W., Hollander, C., Luethy, L.D., Papthanasiou, M., Fargnoli, J., and Holbrook, N.J. "Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents", Mol. Cell. Bio., 9: 41906-44203, Nov. 1989.
Santoro, M.G., Garaci, E., and Amici, C. "Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells", Proc. Natl. Acad. Sci., 86: 8407-8411, Nov. 1989.
Ohno, K., Fukushima, M., Fujiwara, M., and Narunmiya, S. "Induction of 68,000-dalton heat shock proteins by cyclopentenone prostaglandins", J. Bio. Chem., 263: 19764-19770, Dec. 25, 1988.
Hirata, Y., Hayashi, H., Ito, S., Kikawa, Y., Ishibashi, M., Sudo, M., Miyazaki, H., Fukushima, M., Narumiya, S., and Hayaishi, O. "Occurrence of 9-deoxy-.DELTA..sup.9, .DELTA..sup.12 -13, 14-dihydroprostaglandin D.sub.2 in human urine", J. Biol. Chem., 263: 16619-16625, 1988.
Kato, T., Fukushima, M., Kurozumi, S., and Noyri, R. "Antitumor activity of .DELTA..sup.7 -prostaglandin A.sub.1, and .DELTA..sup.12 -prostaglandin J.sub.2 in vitro and in vivo", Cancer Res., 46: 3538-3542, Jul. 1986.
Kikuchi, Y., Myiauchi, M., Oomori, K., Kita, T., Kizawa, I., and Kato, K. "Inhibition of ovarian cancer cell growth in vitro and in nude mice by prostaglandin D.sub.2 ", Cancer Res., 46:3364-3366, Jul. 1986.
Bhuyan, B.K., Adams, E.G., Badiner, G.J., Li, L.H., and Barden, K. "Cell cycle effects of Prostaglandins A.sub.1, A.sub.2 and D.sub.2 in human murine melanoma cells in culture", Cancer Res., 46: 1688-1693, Apr. 1986.
Heavey, D.J., Lumley, P., Barrow, S.E., Murphy, M.B., Humphrey, P.P.A., and Dollery, C.T. "Effects of intravenous infusions of prostaglandin D.sub.2 in man", Prostaglandins, 28: 755-767, Dec. 1984.
Barrow, S.E., Heavey, D.J., Ennis, M., Chappell, CG., Blair, I.A., and Dollery, C.T. "Measurement of prostaglandin D.sub.2 and identification of metabolities in human plasma during intravenous infusion", Prostaglandins 28(6):743-753, Dec. 1984.
Kikawa, Y., Narumiya, S., Fukushima, M., Wakatsuka, H., and Hayaishi, O. "9-Deoxy-.DELTA..sup.9, .DELTA..sup.12 -13,14-dihydroprostaglandin D.sub.2, a metabolite of prostaglandin D.sup.2 formed in human plasma", Proc. Natl. Acad. Sci., 81: 1317-1321, Mar. 1984.
Fitzpatrick, F.A. and Wynalda, M.A. "Albumin catalyzed metabolism of prostaglandin D.sup.2 : Identification of products formed in vitro", J. Biol. Chem., 258: 11713-11718, Mar. 25, 1983.
Simmet, T. and Jaffe, B.M. Inhibition of B-16 melanoma growth in vitro by prostagland in D.sub.2 Prostaglandins, 25: 47-54, Jan. 1983.
Fukushima, M., Kato, T., Ota, K., Arai, Y., Narumiya, S., and Hayaishi, O. "9-deoxy-.DELTA..sup.9 -prostaglandin D.sub.2, a prostaglandin D.sub.2 derivative with potent antineoplastic activity and weak smooth muscle-contracting activities", Biochem. Biophy. Res. Comm., 109: 626-633, Dec. 15, 1982.
Stringfellow, D.A. and Fitzpatrick, F.A. "Prostaglandin D.sub.2 controls metastasis of malignant melanoma cells", Nat., 282: 76-78, Nov. 1979.
Fitzpatrick, F.A. and Stringfellow, D.A. "Prostaglandin D.sub.2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential", Proc. Natl. Acad. Sci., 76: 1765-1769, Apr. 1979.
See-Lasley et al., Manual of Owcology Therapeutics, C.U.Mosby Co., StLouis, 1981, pp. 17,88,404.
Gattoni-Celli Sebastiano
Jenrette, III Joseph M.
McClay Edward F.
Goldberg Jerome D.
Medical University of South Carolina
LandOfFree
Method of treating neoplastic cells with prostaglandin and radia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating neoplastic cells with prostaglandin and radia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating neoplastic cells with prostaglandin and radia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423392